Answers are grounded in this paper and cite their sources.
Retrospective cohort study evaluates C-reactive protein-to-albumin ratio's ability to predict severe acute pancreatitis, suggesting clinical utility.
Acute pancreatitis (AP) has a highly variable clinical course, making early identification of patients at risk of severe acute pancreatitis (SAP) essential for timely management. This study evaluated the ability of the C-reactive protein-to-albumin ratio (CRP/albumin ratio) at hospital admission to predict SAP and compared its performance with established prognostic scoring systems. This retrospective, single-center cohort study included 502 adults admitted with AP between January 2024 and December 2025. Disease severity was classified according to the revised Atlanta classification. The CRP/albumin ratio was calculated at admission and during serial follow-up, and its predictive performance was assessed using receiver operating characteristic (ROC) curve analysis and Firth logistic regression. Overall, 308 patients (61.4%) had mild, 130 (25.9%) had moderately severe, and 64 (12.7%) had severe AP. The admission CRP/albumin ratio was significantly higher in patients with SAP than in those with less severe disease (p<0.001), and the difference persisted during follow-up. The ratio demonstrated acceptable discrimination for SAP, with an area under the curve (AUC) of 0.796 (95% confidence interval [CI]: 0.666-0.925). A cut-off value of 24.89 provided 69.6% sensitivity and 86.0% specificity. Its discriminatory performance was comparable to that of the Acute Physiology and Chronic Health Evaluation II (APACHE II) score (AUC: 0.800; p=0.959). In complete-case multivariable Firth logistic regression involving 66 patients, including 23 with SAP, the CRP/albumin ratio remained independently associated with SAP (odds ratio: 1.035; 95% CI: 1.011-1.072; p<0.001). The admission CRP/albumin ratio may therefore serve as a simple and readily available complementary marker for early risk stratification in AP, although the proposed cut-off requires validation in prospective multicenter studies.
No takes yet. Share an insight, caveat, or question.
Avci et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: